Label
No interactions expected
Color
Green
Green: Administer standard doses
| Interaction Color Code | Clinical Bottom Line | Clinical Effects | Drug 1 effect | Drug 2 dose | Drug 2 effect | Management | |
|---|---|---|---|---|---|---|---|
| Efavirenz LDV/SOF 414 | Green: Administer standard doses | Administer standard doses | Ledipasvir 90 mg with sofosbuvir 400 mg daily | Ledipasvir AUC, Cmin, Cmax all decreased 34%; Sofosbuvir: no significant effect |
|||
| Efavirenz Fluconazole 413 | Green: Administer standard doses | Administer standard doses | AUC increased 16%; Cmax no significant change |
200 mg x 7 days | No significant change |
||
| Efavirenz RAL 412 | Green: Administer standard doses | Administer standard doses | 400 mg x 1 | Raltegravir AUC decreased 36%; Cmin decreased 21%; Cmax decreased 36% |
|||
| Efavirenz Prednisolone 411 | Green: Administer standard doses | Administer standard doses | Potential for increased prednisolone effects (adrenal insufficiency, Cushing?s syndrome). |
20 mg x 1 | Prednisolone AUC decreased 21% |
||
| Efavirenz RTV 410 | Green: Administer standard doses | Administer standard doses | Increased efavirenz and ritonavir effects |
Efavirenz AUC increased 21%; Cmax no significant change |
500 mg Q12H x 8 days | Ritonavir AUC increased 18% after AM dose; Cmax increased 24% after AM dose; AUC no significant change after PM dose; Cmax no significant change after PM dose |
|
| Efavirenz RTV 409 | Green: Administer standard doses | Administer standard doses | Increased efavirenz and ritonavir effects |
Efavirenz AUC increased 21%; Cmax no significant change |
500 mg Q12H x 8 days | Ritonavir AUC increased 18% after AM dose; Cmax increased 24% after AM dose; AUC no significant change after PM dose; Cmax no significant change after PM dose |
|
| Efavirenz Linagliptin 408 | Green: Administer standard doses | Administer standard doses | Possible decrease in antihyperglycemic effects |
Monitor glycemic control |
|||
| Efavirenz Atorvastatin 407 | Green: Administer standard doses | Administer standard doses | Decreased lipid effects |
No significant change |
10 mg daily x 5 days | Atorvastatin AUC decreased 43%; Cmax decreased 14%, Cmin decreased 69%. Atorvastatin and metabolites AUC decreased 32%, Cmin decreased 48%, Cmax decreased 15% |
Monitor for statin efficacy. May need to increase atorvastatin dose |
| Efavirenz Atorvastatin 406 | Green: Administer standard doses | Administer standard doses | Decreased lipid effects |
No significant change |
10 mg daily on days 0-3 and 15-18 | Atorvastatin AUC decreased 43%; Atorvastatin and metabolites AUC decreased 34% |
Monitor for statin efficacy. May need to increase atorvastatin dose |
| Efavirenz Atorvastatin 405 | Green: Administer standard doses | Administer standard doses | Decreased lipid effects |
No significant change |
10 mg daily x 4 days | Atorvastatin AUC decreased 43%, Cmax decreased %14, cmin decreased 69% Atorvastatin and metabolites AUC decreased 32% |
Monitor for statin efficacy. May need to increase atorvastatin dose |
| Efavirenz Buprenorphine / naloxone 404 | Green: Administer standard doses | Administer standard doses | Possible decreased buprenorphine effects |
No significant change |
stable dose for at least 2 weeks | Buprenorphine AUC decreased 49%; Cmax decreased 45%, Cmin decreased 50%; half-life: decreased 29% |
Monitor for signs and symptoms of opioid withdrawal; some patients may need an increase in the buprenorphine dose, though study patients did not go into opioid withdrawal |
| Efavirenz Sertraline 403 | Green: Administer standard doses | Administer standard doses | Decreased sertaline effects |
50 mg daily x 14 days | Monitor for signs and symptoms of depression and titrate sertaline to effect |
||
| Efavirenz Sertraline 402 | Green: Administer standard doses | Administer standard doses | Decreased sertaline effects |
50 mg daily x 14 days | Sertaline decreased 39%, Cmax decreased 29%, Cmin decreased 46% |
Monitor for signs and symptoms of depression and titrate sertaline to effect |
|
| Efavirenz Sertraline 401 | Green: Administer standard doses | Administer standard doses | Decreased sertaline effects |
No significant change |
50 mg daily x 14 days | Sertaline AUC decreased 39%, Cmax decreased 29%, Cmin decreased 46% |
Monitor for signs and symptoms of depression and titrate sertaline to effect |
| Efavirenz Bupropion 400 | Green: Administer standard doses | Administer standard doses | Decreased bupropion effects |
150 mg SR x 1 | Bupropion AUC decreased 55%; Cmax decreased 34%; half-life: decreased 46% |
Monitor for signs and symptoms of depression and titrate bupropion to effect |
|
| Efavirenz Bupropion 399 | Green: Administer standard doses | Administer standard doses | Decreased bupropion effects |
150 mg SR x 1 | Bupropion AUC decreased 55%; Cmax decreased 34%; half-life: decreased 46% |
Monitor for signs and symptoms of depression and titrate bupropion to effect |
|
| Efavirenz Bupropion 398 | Green: Administer standard doses | Administer standard doses | Decreased bupropion effects |
150 mg SR x 1 | Bupropion AUC decreased 55%; Cmax decreased 34% |
Monitor for signs and symptoms of depression and titrate bupropion to effect |
|
| Efavirenz Isavuconazole 397 | Green: Administer standard doses | Administer standard doses | Possible decreased Isavuconazole levels |
monitor for isravucanazole concentrations and anti fungal response |
|||
| Efavirenz DRV 396 | Green: Administer standard doses | Administer standard doses | Potential for increased efavirenz effects |
Efavirenz AUC increased 21%; Cmin increased 17% |
300 mg BID with ritonavir 100 mg BID | Darunavir Cmin decreased 31%; Cmax decreased 15%; AUC decreased 13% |
Monitor for increased risk of efavirenz related side effects. Consider monitoring drug levels |
| Efavirenz RIF 395 | Green: Administer standard doses | Administer standard doses | Decreased efavirenz effects |
Efavirenz AUC decreased 26%; Cmax decreased 20%, Cmin decreased 32% |
600 mg x 7 days | Monitor for antiviral efficacy. May consider increasing efavirenz to 800 mg daily when used with rifampin |
|
| Efavirenz RIF 394 | Green: Administer standard doses | Administer standard doses | Decreased efavirenz effects |
Monitor for antiviral efficacy. May consider increasing efavirenz to 800 mg daily when used with rifampin |
|||
| Efavirenz RIF 393 | Green: Administer standard doses | Administer standard doses | Decreased efavirenz effects |
Efavirenz AUC decreased 26%; Cmax decreased 20% |
600 mg x 7 days | Monitor for antiviral efficacy. May consider increasing efavirenz to 800 mg daily when used with rifampin |
|
| Efavirenz RIF 392 | Green: Administer standard doses | Administer standard doses | Decreased efavirenz effects |
Efavirenz AUC decreased 22%; Cmax decreased 24%; Cmin decreased 25% |
600 mg daily x 14 days | No significant change |
Monitor for antiviral efficacy. May consider increasing efavirenz to 800 mg daily for patient's weighing 50 kg or more when used with rifampin |
| Efavirenz Diltiazem 391 | Green: Administer standard doses | Administer standard doses | Decreased diltiazem effects |
EFV AUC increased 11%, Cmax increased %16, Cmin increased 13% |
240 mg daily x 14 days | Monitor diltiazem efficacy and to titrate to clinical effect |
|
| Efavirenz Diltiazem 390 | Green: Administer standard doses | Administer standard doses | Decreased diltiazem effects |
No significant change |
240 mg daily x 21 days | Diltiazem AUC decreased 69%; Cmax decreased 60%; Cmin decreased 63% |
Monitor diltiazem efficacy and to titrate to clinical effect |
| Efavirenz Diltiazem 389 | Green: Administer standard doses | Administer standard doses | Decreased diltiazem effects |
No significant change |
240 mg daily x 21 days | Diltiazem AUC decreased 69%; Cmax decreased 60%; Cmin decreased 63% |
Monitor diltiazem efficacy and to titrate to clinical effect |
| Efavirenz Diltiazem 388 | Green: Administer standard doses | Administer standard doses | Decreased diltiazem effects |
No significant change |
240 mg daily x 21 days | Diltiazem AUC decreased 69%; Cmax decreased 60%; Cmin decreased 63% |
Monitor diltiazem efficacy and to titrate to clinical effect |
| Doravirine Ketoconazole 346 | Green: Administer standard doses | Administer standard doses | Potential for increased doravirine adverse effects |
AUC increased to 306%; Cmax increased by 25%; C24 increased to 275% |
400 mg daily | Not studied |
No dose adjustment necessary. Monitor for doravirine adverse effects. |
| Doravirine RTV 345 | Green: Administer standard doses | Administer standard doses | Potential for increased doravirine adverse effects |
AUC increased to 354%; Cmax increased by 31%; C24 increased to 291% |
100 mg BID | Not studied |
No dose adjustment necessary. Monitor for doravirine adverse effects. |
| Doravirine Omeprazole 344 | Green: Administer standard doses | Administer standard doses | Potential decrease in antiretroviral efficacy. |
AUC decreased 17%; Cmin decreased 16% |
|||
| Cabotegravir ETR 332 | Green: Administer standard doses | Administer standard doses | Cmax increased 4%, AUC increased 1% |
200 mg once daily | Not studied |
||
| Cabotegravir Midazolam 331 | Green: Administer standard doses | Administer standard doses | Not studied |
3mg | Cmax increased 9%, AUC increased 10% |
||
| Cabotegravir LNG 330 | Green: Administer standard doses | Administer standard doses | Not studied |
0.15 mg once daily | Cmax increased 5%, AUC increased 12%, Cmin increased 7% |
||
| Cabotegravir EE/NGM 329 | Green: Administer standard doses | Administer standard doses | Not studied |
0.03mg once daily | Cmax decreased 8%, AUC increased 2% |
||
| Cabotegravir RPV 328 | Green: Administer standard doses | Administer standard doses | Cmax increased 5%, AUC increased 12%, Cmin increased 14% |
25 mg once daily | Cmax decreased 4%, AUC decreased 1%, Cmin decreased 8% |
||
| Cabotegravir RFB 327 | Green: Administer standard doses | Administer standard doses | Cmax decreased 17%, AUC decreased 23%, Cmin decreased 26% |
300 mg once daily | Not studied |
||
| Raltegravir Dasabuvir + Ombitasvir / Paritaprevir / Ritonavir 316 | Green: Administer standard doses | Administer standard doses | Raltegravir AUC increased 134% |
paritaprevir 150 mg with ritonavir 100 mg with ombitasvir 25 mg daily + dasabuvir 250 mg BID | |||
| Raltegravir DRV 315 | Green: Administer standard doses | Administer standard doses | Raltegravir AUC decreased 29%; Cmin increased 38%; Cmax decreased 33% |
600 mg Q12H with 100 mg ritonavir Q12H | |||
| Raltegravir RPV 314 | Green: Administer standard doses | Administer standard doses | Raltegravir Cmin increased 27% |
25 mg daily | |||
| Raltegravir SOF 313 | Green: Administer standard doses | Administer standard doses | No significant change |
400 mg x 1 | Sofosbuvir Cmax decreased 43%; AUC decreased 27% |
||
| Raltegravir SOF/VEL 312 | Green: Administer standard doses | Administer standard doses | Raltegravir Cmin increased 8%; AUC increased 5%. |
400 mg / 100 mg | Not reported |
||
| Raltegravir G/P 311 | Green: Administer standard doses | Administer standard doses | Raltegravir AUC increased 47%; Cmin increased 164% |
300 / 120 mg daily | Not reported |
||
| Raltegravir ATV 310 | Green: Administer standard doses | Administer standard doses | RAL AUC no significant change |
300 mg BID | Not reported |
||
| Raltegravir ETR 309 | Green: Administer standard doses | Administer standard doses | Raltegravir AUC decreased 10%; Cmin decreased 34% |
200 mg BID | Not reported |
||
| Raltegravir RTV 308 | Green: Administer standard doses | Administer standard doses | Raltegravir AUC decreased 16%; Cmax decreased 24% |
100 mg BID | Not reported |
||
| Raltegravir Buprenorphine / naloxone 307 | Green: Administer standard doses | Administer standard doses | No significant change |
stable dose for at least 3 weeks | No significant change |
||
| Raltegravir EBR/GZR 306 | Green: Administer standard doses | Administer standard doses | Increase RAL AUC 43% with grazoprevir |
Elbasvir 50 mg daily with grazoprevir 100 mg daily | No significant change |
||
| Raltegravir LDV/SOF 305 | Green: Administer standard doses | Administer standard doses | Raltegravir AUC decreased 15-27% |
90 / 400 mg daily | No significant change |
||
| Raltegravir Pravastatin 304 | Green: Administer standard doses | Administer standard doses | Raltegravir Cmax increased 31%; Cmin decreased 41% |
40 mg daily | No significant change |
||
| Raltegravir Pravastatin 303 | Green: Administer standard doses | Administer standard doses | Raltegravir AUC no significant change; Cmax increased 31%; Cmin decreased 41% |
40 mg daily | No significant change |
||
| Raltegravir Midazolam 302 | Green: Administer standard doses | Administer standard doses | 2 mg x 1 | No significant change |
|||
| Raltegravir Lamotrigine 301 | Green: Administer standard doses | Administer standard doses | 100 mg | No significant change |
|||
| Raltegravir MVC 300 | Green: Administer standard doses | Administer standard doses | Raltegravir AUC decreased 37%; Cmin decreased 28%; Cmax decreased 33% |
300 mg Q12H | Maraviroc Cmin decreased 21%; Cmax decreased 20% |
||
| Raltegravir ETR 299 | Green: Administer standard doses | Administer standard doses | Not reported |
200 mg | Etravirine AUC increased 10%, Cmin increased 17% |
||
| Raltegravir Ginkgo biloba 298 | Green: Administer standard doses | Administer standard doses | No significant change |
120 mg BID | Ginkgo biloba AUC increased 21%; Cmax increased 44% |
||
| Raltegravir Omeprazole 297 | Green: Administer standard doses | Administer standard doses | Raltegravir AUC increased 39%; Cmax increased 50%; Cmin increased 24% |
20 mg daily | Not reported |
||
| Raltegravir Omeprazole 296 | Green: Administer standard doses | Administer standard doses | Raltegravir AUC increased 212%; Cmin increased 46%; Cmax increased 315% |
20 mg daily x 4 days | |||
| Raltegravir Famotidine 295 | Green: Administer standard doses | Administer standard doses | Raltegravir AUC increased 45%; Cmax increased 60% |
20 mg daily given 2 hours before raltegravir | |||
| Raltegravir Calcium carbonate 294 | Green: Administer standard doses | Administer standard doses | Raltegravir AUC decreased 55%; Cmin decreased 32% |
3000 mg single dose | Not reported |
||
| Raltegravir ATV 293 | Green: Administer standard doses | Administer standard doses | Potential for increased raltegravir effects |
Raltegravir AUC increased 72%; Cmax increased 53%; Cmin increased 95% |
400 mg daily | ||
| Raltegravir ATV 292 | Green: Administer standard doses | Administer standard doses | Potential for increased raltegravir effects |
Raltegravir AUC increased 41%; Cmax increased 24%; Cmin increased 77% |
300 mg with 100 mg ritonavir daily | ||
| Raltegravir ATV 291 | Green: Administer standard doses | Administer standard doses | Potential for increased raltegravir effects |
Raltegravir AUC increased 67% |
400 mg daily | Not reported |
|
| Raltegravir TDF 290 | Green: Administer standard doses | Administer standard doses | Potential for increased raltegravir effects |
Raltegravir AUC increased 49%; Cmax increased 64% |
300 mg daily | Not reported |
|
| Raltegravir ATV 289 | Green: Administer standard doses | Administer standard doses | Potential for increased raltegravir effects |
Raltegravir AUC increased 54%; Cmin increased 48%; Cmax increased 39% |
300 mg BID on days 6-12 and days 13-26 | Atazanavir AUC decreased 17%; Cmin decreased 29% (compared to atazanavir BID) |
|
| Raltegravir EFV 288 | Green: Administer standard doses | Administer standard doses | Potential decrease in antiretroviral efficacy |
Raltegravir AUC decreased 36%; Cmax 36%; Cmin decreased 21% |
600 mg daily | Not reported |
|
| Raltegravir EFV 287 | Green: Administer standard doses | Administer standard doses | Potential decrease in antiretroviral efficacy |
Raltegravir AUC decreased 14% |
600 mg daily | Not reported |
|
| Raltegravir RPT 286 | Green: Administer standard doses | Adjust dosing to avoid reduced levels of raltegravir | Potential for increased raltegravir adverse effects if given with rifapentine once weekly; potential for loss of antiviral response if rifapentine coadministered daily |
When given with rifapentine once weekly for 3 weeks raltegravir AUC increased 79%, Cmax increased 89% and Cmin decreased 12%. When given with rifapentine for 10 daily doses, Cmin decreased 41% |
900 mg once weekly for 3 weeks or 600 mg once daily for 10 scheduled doses (days 1, 4?8 and 11?14) | When coadministering with once weekly rifapentine use raltegravir 400 mg BID. Do not coadminister raltegravir with once daily rifapentine. |
|
| Elvitegravir G/P 181 | Green: Administer standard doses | Administer standard doses | Potential increase in GLEC / PIB toxicity |
AUC increased 47% |
Glecaprevir AUC increased 3 fold; PIB AUC increased 57% |
||
| Elvitegravir Ethosuximide 180 | Green: Administer standard doses | Administer standard doses | Potential for increased anticonvulsant effects |
Monitor for ethosuximide adverse effects |
|||
| Elvitegravir Clonazepam 179 | Green: Administer standard doses | Administer standard doses | Potential for increased clonazepam effects (e.g. sedation, respiratory depression) |
Frequent clinical monitoring is recommended |
|||
| Elvitegravir Lamotrigine 178 | Green: Administer standard doses | Administer standard doses | Potential for increased anticonvulsant effects |
Frequent clinical monitoring is recommended |
|||
| Elvitegravir SOF/VEL 141 | Green: Administer standard doses | Administer standard doses | Stribild is coformulated with tenofovir disoproxil fumarate and TDF levels are increased by sofosbuvir / velpatasvir. |
Cmax decreased 13%; AUC decreased 6%; Cmin increased 8% |
400 / 100 mg once daily | Velpatasvir Cmax increased 30%, AUC increased 50%, Cmin increased 60%; Sofosbuvir Cmax increased 23%, AUC increased 37%; Sofosbuvir metabolite Cmax increased 29%, AUC increased 48%, Cmin increased 58% |
Monitor TDF-related adverse reactions |
| Elvitegravir SOF/VEL/VOX 140 | Green: Administer standard doses | Administer standard doses | Cmax decreased 21%; AUC decreased 6%; Cmin increased 32% |
400 / 100 / 100 mg plus 100 mg voxilaprevir | Voxilaprevir Cmax increased 92%; AUC increased 171%; Cmin increased 350%. Velpatasvir AUC increased 16%; Cmin increased 46%. Sofosbuvir Cmax increased 27%; AUC increased 22% |
If coadministering with Stribild, monitor for TDF related adverse effects. Consider monitoring for hepatotoxicity when coadministering with either Stribild or Genvoya |
|
| Elvitegravir Famotidine 134 | Green: Administer standard doses | Administer standard doses | No significant change in AUC or Cmax when administered 12 hours apart or if administered simultaneously |
40 mg given 12 hours after EVG or 40 mg given simultaneously with EVG | Not reported |
||
| Elvitegravir Omeprazole 133 | Green: Administer standard doses | Administer standard doses | If omeprazole given 2 hours before EVG, Cmax increased 16%, AUC increased 10%, Cmin increased 13%. If given 12h after, no significant change. |
20 mg given 2 hours before or 12 hours after elvitegravir | Not reported |
||
| Elvitegravir Methadone 132 | Green: Administer standard doses | Administer standard doses | Not reported |
80-120 mg daily | No significant change in R-methadone or S-methadone |
||
| Elvitegravir Sertraline 131 | Green: Administer standard doses | Administer standard doses | Cmax decreased 12%; AUC decreased 6% |
50 mg single dose | Cmax increased 14%; AUC decreased 7% |
||
| Elvitegravir Naloxone 130 | Green: Administer standard doses | Administer standard doses | Potential reduced efficacy of naloxone |
Not reported |
4-6 mg once daily | Cmax and AUC decrease 28% |
|
| Elvitegravir Buprenorphine / naloxone 129 | Green: Administer standard doses | Administer standard doses | Potential for increased risk of sedation and decreased cognition |
Not reported |
16-24 mg once daily | Buprenorphine Cmax increased 12%, AUC increased 35%, Cmin increased 66%. Norbuprenorphine metabolite Cmax increased 24%, AUC increased 42%, Cmin increased 57% |
If using, monitor closely for excess sedation and cognitive effects |
| Dolutegravir SOF/VEL 112 | Green: Administer standard doses | Administer standard doses | Not studied |
400 / 100 mg daily | Sofosbuvir Cmax decreased 12%, AUC decreased 8%. No significant change in sofosbuvir metabolite GS-331007. Velpatasvir Cmax decreased 6%, AUC decreased 9%, Cmin decreased 12%. |
||
| Dolutegravir DRV/r 111 | Green: Administer standard doses | Administer standard doses | Cmax decreased 11%, AUC decreased 22%, Cmin decreased 38% |
600 / 100 mg once daily | Not studied |
||
| Dolutegravir Prednisone 110 | Green: Administer standard doses | Administer standard doses | Cmax increased 6%, AUC increased 11%, Cmin increased 17% |
60 mg daily with taper | Not studied |
||
| Dolutegravir ATV 109 | Green: Administer standard doses | Administer standard doses | Cmax increased 50%, AUC increased 91%, Cmin increased 180% |
400 mg once daily | Not studied |
||
| Dolutegravir Omeprazole 108 | Green: Administer standard doses | Administer standard doses | No significant change |
40 mg once daily | Not studied |
||
| Dolutegravir ATV/r 107 | Green: Administer standard doses | Administer standard doses | Cmax increased 34%, AUC increased 62%, Cmin increased 121% |
300 / 100 mg once daily | Not studied |
||
| Dolutegravir ETR + DRV/r 106 | Green: Administer standard doses | Administer standard doses | Cmax decreased 12%, AUC decreased 25%, Cmin decreased 37% |
200 mg + 600 / 100 mg BID | Not studied |
||
| Dolutegravir EBR/GZR 105 | Green: Administer standard doses | Administer standard doses | Cmax increased 22%, AUC increased 16%, Cmin increased 14% |
elbasvir 50 mg + grazoprevir 200 mg once daily | No significant change in elbasvir. Grazoprevir Cmax decreased 36%, AUC decreased 19%, Cmin decreased 14% |
||
| Dolutegravir Daclatasvir 104 | Green: Administer standard doses | Administer standard doses | Cmax increased 29%, AUC increased 33%, Cmin increased 45% |
60 mg once daily | No significant change |
||
| Dolutegravir Midazolam 103 | Green: Administer standard doses | Administer standard doses | Not studied |
3 mg | No significant change |
||
| Dolutegravir Methadone 102 | Green: Administer standard doses | Administer standard doses | Not studied |
16-150 mg | No significant change |
||
| Dolutegravir Norelgestromin 101 | Green: Administer standard doses | Administer standard doses | No significant change |
0.25 mg | No significant change |
||
| Dolutegravir EE/NGM 100 | Green: Administer standard doses | Administer standard doses | No significant change |
0.035 mg ethinyl estradiol + norelgestromin 0.25 mg | No significant change |
||
| Dolutegravir TDF 99 | Green: Administer standard doses | Administer standard doses | Cmax decreased 3%, AUC increased 1%, Cmin decreased 8% |
300 mg once daily | Cmax increased 9%, AUC increased 12%, Cmin increased 19% |
||
| Dolutegravir RPV 98 | Green: Administer standard doses | Administer standard doses | Cmax increased 13%, AUC increased 12%, Cmin increased 22% |
25 mg once daily | Cmax increased 10%, AUC increased 6%, Cmin increased 21% |
||
| Dolutegravir RFB 97 | Green: Administer standard doses | Administer standard doses | Cmax increased 16%, AUC decreased 5%, Cmin decreased 30% |
300 mg once daily | Not studied |
||
| Bictegravir SOF/VEL/VOX 70 | Green: Administer standard doses | Administer standard doses | Cmax decreased 2%, AUC increased 7%, Cmin increased 10% |
400 / 100 / 100 + 100 voxilaprevir once daily (fed state) | Sofosbuvir Cmax increased 14%, AUC increased 9%. Velpatasvir Cmax decreased 4%, AUC decreased 4%, Cmin decreased 6%. Voxilaprevir Cmax decreased 10%, AUC decreased 9%, Cmin decreased 3% |
||
| Bictegravir LDV/SOF 69 | Green: Administer standard doses | Administer standard doses | Cmax decreased 2%, Cmin increased 4% |
90 / 400 mg once daily | Ledipasvir Cmax decreased 15%, AUC decreased 13%. Sofosbuvir Cmax increased 11%, AUC increased 7% |
||
| Bictegravir EE/NGM 68 | Green: Administer standard doses | Administer standard doses | Not reported |
EE 0.025mg once daily with NGM 0.180 / 0.215 / 0.250mg once daily | Ethinyl estradiol Cmax inccreased 15%, AUC increased 4%, Cmin increased 5%. Norelgestromin Cmax increased 23%, AUC increased 8%, Cmin increased 10%. Norgestrel Cmax increase 15%, AUC increase 13%, Cmin increase 14% |
||
| Bictegravir Midazolam 67 | Green: Administer standard doses | Administer standard doses | Potential for increased sedation |
Not reported |
2 mg single dose | Cmax increased 3%, AUC increased 15% |
|
| Bictegravir Metformin 66 | Green: Administer standard doses | Administer standard doses | Potential increase in metformin adverse effects (gastrointestinal) |
Not reported |
500 mg BID | Cmax inccreased 28%, AUC increased 39%, Cmin increased 36% |
